^
Association details:
| Biomarker: | NLRC5 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
Published date:
02/05/2021
Excerpt:
Melanoma tumors derived from patients responding to immunotherapy exhibited significantly higher expression of NLRC5 and MHC class I-related genes compared to non-responding patients...These results suggest that NLRC5 tumor expression, alone or together with tumor mutation load constitutes a valuable predictive biomarker for both prognosis and response to anti-CTLA-4 and potentially anti-PD1 blockade immunotherapy in melanoma patients.
DOI:
10.1038/s41598-021-82729-9
